- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
First Helium
Black Swan Graphene
Metals Australia
CVD Equipment Corporation
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
ResMed revealed the lightweight and portable AirMini, a CPAP machine designed for people with sleep apnea.
ResMed (NYSE:RMD) revealed the lightweight and portable AirMini, a CPAP (continuous positive airway pressure) machine for people with sleep apnea.
As quoted in the press release:
“The ResMed AirMini has redefined CPAP therapy – providing patients with peace of mind, knowing they can easily get ResMed-quality therapy wherever they are,” said Mick Farrell, ResMed CEO. “CPAP is now more portable and accessible than ever before. I have been traveling all over the world with a prototype of the AirMini system, using AutoSet, humidification, and an AirFit™ P10 pillows mask, and it has changed my travel life. I am so excited to see that this technology is now available to many millions of sleep apnea patients.”
In a recent survey, 65% of CPAP users said device size is the #1 reason they don’t take their CPAP every time they travel, breaking the cycle of adherence and exposing themselves to sleep apnea’s chronic effects: they stop breathing repeatedly throughout the night, unconsciously transitioning between moments of sleep suffocation and jolts of awakening to resume breathing. This may cause dangerous levels of daytime fatigue and raise the risk of developing other fatal conditions like type 2 diabetes and heart failure.
Click here to read the full press release.
Source: www.multivu.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.